This was not a crash database, a roadside field study, or a randomized dosing trial. Frequent cannabis users smoked their own preferred product at home the evening before, then completed next-morning driving-simulator and cognitive testing 12 to 15 hours later.

That design is useful because it studies the real residual phase that patients care about. It is also limiting because the amount, potency, route details, and tolerance profile were not standardized the way they would be in a tightly controlled dosing experiment.

The more clinically persuasive signal came from oral fluid, not blood. Participants with oral-fluid THC at or above 25 ng/mL performed worse on Trail Making Test A and B, with large effect sizes that remained significant after correction for multiple comparisons.

By contrast, several blood-THC and driving-simulator differences looked directionally concerning but did not survive the same statistical correction. That means the study does not support treating the common blood cutoff as a reliable single marker of next-morning functional impairment.

The study does not prove that a person below the tested thresholds is safe to drive, or that everyone above them is functionally impaired in the same way. Detection thresholds measure biology more directly than real-world judgment, divided attention, self-awareness, or road behavior.

That distinction matters because legal and clinical conversations often collapse exposure, impairment, and risk into one category. This paper argues against that shortcut.

Frequent users are exactly the group most likely to assume that familiarity equals morning-after readiness. This study gives clinicians a better way to explain why tolerance and residual cannabinoids do not automatically erase cognitive risk.

It also reinforces that oral-fluid and blood measures may not perform the same way in the residual phase, which matters for medicolegal counseling and patient expectations.

Use the study to make counseling more specific, not more absolute. Patients who use cannabis frequently should hear that evening use can still leave measurable next-morning cognitive effects, even when the driving signal is not cleanly captured by one threshold.

What this paper does not justify is a new universal waiting-period rule or a confident claim that one test type has solved the cannabis-impairment problem. It justifies caution, context, and more honest discussion.

Cannabis impairment research keeps colliding with a simple public desire for one number that settles the question. Blood THC, oral-fluid THC, subjective confidence, and simulator performance all measure different parts of the problem.

That is why this paper is valuable even without a perfect rule. It helps clinicians push back on the false certainty that often surrounds next-morning cannabis discussions.

What stands out here is not that the study solved the morning-after driving question. It is that the paper demonstrates why the question resists simple thresholds in the first place.

The most defensible counseling message is still conservative: if a patient uses cannabis heavily or regularly, especially in the evening, next-morning driving should not be treated casually just because intoxication no longer feels obvious.

Four questions worth asking before you simplify the result